This regulatory mechanism not only suppresses IGF2BPs, a promoter of tumor progression, but also activates RIG‐I‐MAVS signaling, potentially enhancing immune response within the tumor microenvironment.[151] In addition, LINRIS enhances CRC progression by stabilizing IGF2BP2 through inhibition of its ubiquitination at K139. The gene discussed is MAVS; the disease is neoplasm.